| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Departments of Urology (A.S., C.Y.F.Y.) and Biochemistry and Molecular Biology (W.Z., C.Y.F.Y.), Mayo Graduate School, Mayo Clinic/Foundation, Rochester, Minnesota 55905
Address all correspondence and requests for reprints to: Charles Young, Mayo Clinic/Foundation, 200 1st Street SW, Department of Urology, Rochester, Minnesota 55905.
 |
Abstract |
|---|
 Top Abstract |
|---|
Nonsteroidal anti-inflammatory drugs (NSAIDs) play potential roles in chemoprevention of colon cancer and others by inhibiting prostaglandin synthesis. In this report, we used LNCaP cells, an androgen-responsive human prostate carcinoma cell line, to study the effects of two NSAIDs, flufenamic acid (FA) and piroxicam (PXM), on the cancer cell growth stimulated by androgens. We found that FA had much higher potency to inhibit LNCaP cell growth than PXM. FA dramatically reduced the expression of androgen inducible genes, such as prostate-specific antigen (PSA) and the homeo-domain transcription factor Nkx3.1, but PXM did not. In vitro transfection experiments showed that FA down regulated the PSA expression at the transcription level. Western and northern blot analyses demonstrated that FA inhibited the androgen receptor (AR) expression at mRNA and protein levels. Suppressed AR expression may be the cause of FA-mediated inhibition of the androgen inducible gene expression. Our data also showed that FA significantly reduced the AR promoter-mediated transcription activities. This study indicated that AR might be a target for FA to inhibit LNCaP cell growth. FA and other similar NSAIDs may be potential candidates for chemoprevention of human prostate cancer by modulating the expression of AR.
Received June 25, 1999.
This article has been cited by other articles:
 |
|
 |
|
  J. L. St. Sauver, D. J. Jacobson, M. E. McGree, M. M. Lieber, and S. J. Jacobsen Protective Association between Nonsteroidal Antiinflammatory Drug Use and Measures of Benign Prostatic Hyperplasia Am. J. Epidemiol., October 15, 2006; 164(8): 760 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Debes, B. Comuzzi, L. J. Schmidt, S. M. Dehm, Z. Culig, and D. J. Tindall p300 Regulates Androgen Receptor-Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6 Cancer Res., July 1, 2005; 65(13): 5965 - 5973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z Culig, H Steiner, G Bartsch, and A Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Cho, C. Jiang, B. Malewicz, Y. Dong, C. Y.F. Young, K.-S. Kang, Y.-S. Lee, C. Ip, and J. Lu Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription Mol. Cancer Ther., May 1, 2004; 3(5): 605 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. E. Lim, G. A. Piazza, R. Pamukcu, W. J. Thompson, and I. B. Weinstein Exisulind and Related Compounds Inhibit Expression and Function of the Androgen Receptor in Human Prostate Cancer Cells Clin. Cancer Res., October 15, 2003; 9(13): 4972 - 4982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Pan, J.-S. Zhang, M. H. Gazi, and C. Y. F. Young The Cyclooxygenase 2-specific Nonsteroidal Anti-inflammatory Drugs Celecoxib and Nimesulide Inhibit Androgen Receptor Activity via Induction of c-Jun in Prostate Cancer Cells Cancer Epidemiol. Biomarkers Prev., August 1, 2003; 12(8): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Debes, L. J. Schmidt, H. Huang, and D. J. Tindall p300 Mediates Androgen-independent Transactivation of the Androgen Receptor by Interleukin 6 Cancer Res., October 15, 2002; 62(20): 5632 - 5636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Leitzmann, M. J. Stampfer, J. Ma, J. M. Chan, G. A. Colditz, W. C. Willett, and E. Giovannucci Aspirin Use in Relation to Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1108 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Roberts, D. J. Jacobson, C. J. Girman, T. Rhodes, M. M. Lieber, and S. J. Jacobsen A Population-Based Study of Daily Nonsteroidal Anti-inflammatory Drug Use and Prostate Cancer Mayo Clin. Proc., March 1, 2002; 77(3): 219 - 225. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Zhu, J.-S. Zhang, and C. Y.F. Young Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP Carcinogenesis, September 1, 2001; 22(9): 1399 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Xing, Y. Chen, S. H. Mitchell, and C. Y.F. Young Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells Carcinogenesis, March 1, 2001; 22(3): 409 - 414. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
